论文部分内容阅读
异常凝血酶原(APT)是近年来发现的一种比较理想的肝癌肿瘤标志物,对2cm 以上肝癌的检出率至少已与AFP 相当。APT 的升高与AFP无关,两者联合检测可大辐度提高肝癌的检出率。APT 对肝癌的诊断具有较好的特异性,慢性肝炎、肝硬化、良性占位性病变等肝脏疾病与肝癌的APT 水平较少发生重叠。将APT 用于监测慢性肝炎、肝硬化等癌前病变向肝癌的转化以及肝癌治疗效果评价亦取得较好的结果。本文就APT 的产生机制、理化性质、临床意义和测定方法进行了综述。
Abnormal prothrombin (APT) is an ideal hepatoma tumor marker discovered in recent years. The detection rate of liver cancer above 2 cm is at least equal to that of AFP. The increase in APT is not associated with AFP, and the combined detection of the two can greatly increase the detection rate of liver cancer. APT has a good specificity for the diagnosis of liver cancer. Liver diseases such as chronic hepatitis, liver cirrhosis, and benign space-occupying lesions rarely overlap with liver cancer APT levels. APT was used to monitor the transformation of chronic hepatitis, liver cirrhosis and other precancerous lesions into liver cancer, and the evaluation of therapeutic effects of liver cancer also achieved good results. This article reviews the production mechanism, physicochemical properties, clinical significance, and measurement methods of APT.